Antirestenotic Mechanisms of Everolimus on Human Coronary Artery Smooth Muscle Cells: Inhibition of Human Coronary Artery Smooth Muscle Cell Proliferation, but not Migration

作者：Lavigne Mark C; Grim**y Jessica L; Eppihimer Michael J^*

来源：Journal of Cardiovascular Pharmacology, 2012, 59(2): 165-174.

DOI：10.1097/FJC.0b013e31823a39c7

• everolimus
• vascular smooth muscle
• proliferation
• migration
• drug-eluting stent
• cell signaling

Everolimus, a pharmaceutical component of drug-eluting stents, inhibits coronary vessel restenosis, but the anti-restenotic mechanisms of action remain unclear. Here, we describe the effects of everolimus on key contributors to vessel restenosis, smooth muscle cell proliferation, and migration. In a dose-dependent fashion, everolimus reduced human coronary artery smooth muscle cell (HCASMC) proliferation without toxicity in a bimodal fashion, with accentuated potency occurring at 10 mu M. Everolimus arrested the majority of HCASMCs in G1-phase, whereas it reduced the fraction of cells in S-phase at doses that inhibited DNA synthesis (bromodeoxyuridine incorporation). Consistent with this, Western blotting demonstrated that everolimus reduced activation and expression of G1-phase cell cycle progression factors, including p70S6K and cyclin D, respectively, decreased levels of proliferating cell nuclear antigen, and attenuated growth factor/serum-induced phosphorylation of the cell cycle phase transition intermediate, retinoblastoma protein. Everolimus did not, however, affect HCASMC migration. These observations suggest that everolimus acts as an anti-proliferative, but not antimigratory, compound to account for at least some of the clinical efficacy exhibited by this drug as an antirestenotic agent. Moreover, everolimus-induced inhibition of the mammalian target of rapamycin complex 1 and regulation of cyclin-mediated cell cycle progression actions likely account for the antiproliferative effects of this compound on HCASMCs.

• 出版日期2012-2